Network Partners

Why Network Partners are so Strategic

The Starzl Network aims to accelerate progress in transplantation by connecting transplant thought leaders, tech innovators and industry leaders to work together to solve the challenges our patients and families have identified as priority areas. Partners from health care, industry, and charitable foundations allow us to strategically expand the reach and impact of the network.

Our goal, as Dr. Starzl hoped, is to measure children’s outcomes not in years or even decades, but in lifetimes. We invite you to join us in this quest.

The Starzl Network is grateful for the strategic support and commitment of the following partners:

The Starzl Network is Powered by

More information about Citrone 33’s transformational gift can be found here

2021-2022 Starzl Network Supporters

Disruptor Level

Visionary Level

Innovator Level

Collaborator Level

Partner Level


Henry L. Hillman Foundation works to ensure that Pittsburgh’s considerable strengths, assets, and advantages are fully leveraged to make it one of the world’s most innovative and forward-looking cities, with a reputation for solving big problems through civic leadership and collaboration.

Henry L. Hillman Foundation has a broad interest in initiatives that are timely and designed to take advantage of an emerging opportunity. The Foundation will prioritize investments that align with the following “portfolio” focus areas: Aging Well, Big Ideas and New Models, Capturing the Next Economy, Healthy Neighborhoods, Strengthening Democracy, and Sustainable Regional Infrastructure.

OmniLife is a nationally recognized communication technology platform dedicated to the unique needs of transplant and donation professionals. Over the past four years, the company has built the nation’s largest communication and collaboration network dedicated completely to the unique needs of transplant and donation professionals.

OmniLife’s founders were recognized in the 2018 HealthCare edition of Forbes 30 Under 30. The company was recently awarded $2M in Phase I & II grants by the National Institutes of Health (NIH) Small Business Innovation Research (SBIR), with the resulting Phase I study showing promising results which have been accepted for publication in the industry journal “Progress in Transplantation.” OmniLife’s technology has been incorporated into donation and transplant specialties nationally and has facilitated over 1,000 life-saving transplants to date.

CareDx is committed to improving transplant patient outcomes through innovative, noninvasive testing solutions and services throughout the entire patient journey. Our understanding of transplant patients and care teams allows us to develop solutions to extend graft life – one of which is AlloSure, an emerging standard of care for kidney transplant patients, used in over 150 U.S. transplant centers and over 30,000 patients. With two decades of commitment to transplant care, CareDx has developed close partnerships across the transplant ecosystem that grow stronger every day. Click here (PDF) to learn more about Utility of AlloSure in Pediatric Kidney Transplant Patients.

Medistim is a market leader within intra-operative transit time flow measurement (TTFM) and ultrasound imaging, providing the MiraQ™ system to the global market. These systems enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery.  They provide clinically relevant information that empowers surgeons to make better-informed decisions in the operating room.

Transit time flow measurement (TTFM) is a well-established, easy to use, and rapid quality control method in liver transplantation. The real-time flow volume and pressure information obtained with Medistim’s systems accurately guides the surgeon on the hepatic regional hemodynamic status and response during inflow modulation. This yields a reliable overview of the transplanted liver function before patient closure.

Simultaneous flow and pressure measurements with Medistim systems provide effective guidance for potential flow modulation procedures and in optimizing the liver hemodynamics. To learn more about how our technology is used in Liver Transplant surgery, please click here.

The Center for Organ Recovery & Education (CORE) is one of 57 federally designated not-for-profit organ procurement organizations (OPOs) in the United States, serving more than five million people in western Pennsylvania, West Virginia and Chemung County, NY.

CORE partners with more than 150 hospitals and health care facilities, as well as funeral directors, coroners and medical examiners, to offer hope and a second chance at life to the more than 100,000 people who are waiting nationwide for life-saving and healing organ, tissue and corneal transplants. CORE is also entrusted with the privilege of supporting donor families during the donation process and beyond.

CORE’s mission is to Save and Heal lives through donation, and we do so while always maintaining respect for the donor and integrity for the donation process. CORE also works

tirelessly to create a culture of donation within the hospitals and communities we serve. Our hope is that through innovation and by fostering a greater understanding of donation and transplantation, we offer hope to those waiting, while also honoring the truest heroes of donation: the donors and their families.

In 2020, CORE made possible 792 life-saving organ transplants and as many as 90,000 tissue and corneal transplants, thanks to the generosity of 324 organ donors and more than 1,000 tissue and cornea donors.

CORE is a winner of the 2019 Malcolm Baldrige National Quality Award, a presidential-level honor that recognizes non-profits for their excellence.

Plexision develops cellular biomarkers for personalized diagnostics and drug development in infectious diseases, solid organ transplantation, as well as immuno-oncology. These tests are based on patented technology that measures antigen-specific white blood cells. Testing services for patients, researchers, and drug developers are provided by Plexision’s CLIA-certified, GMP-compliant central laboratory in Pittsburgh, Pennsylvania. Plexision’s team consists of highly-trained technologists, cytometrists, clinicians, scientists, bioentrepreneurs, and bioinformaticians.

Plexision currently offers a wide array of lab-developed cell-based diagnostic tests for personalized patient care. The patented technology underlying these testing systems has been used to support custom R&D projects in both the industry and academia.

Plexision’s first product, the FDA-approved Pleximmune blood test predicts transplant rejection. PlexCOVID-19, the most recent blood test, measures the risk and severity of COVID-19 infection.

Our technology can be adapted to –

  • Assess disease risk for several immunological disorders.
  • Predict the success of a drug for a specific patient.
  • Develop dosing recommendations for new immunological drugs.

Why We Started

What is a Learning Health System

In 2006, the Institute of Medicine (IOM) convened a Roundtable on Evidence-Based Medicine to explore innovative strategies for improving health care. IOM’s guiding principle was that medical decision-making and health care systems should be “grounded on a reliable evidence base,” “account for individual variation in patient needs,” and facilitate “the generation of new insights on clinical effectiveness.”1 To realize these goals, the IOM experts envisioned implementing learning health systems (LHS), which would be built to enable “continuous improvement and innovation, with best practices seamlessly embedded in the delivery process and new knowledge captured as an integral byproduct of the delivery experience.”2 LHS aim to integrate research, improvement, management, and patient care such that every patient receives “the right care at the right time…every time.”3 Critical to a successful LHS is the integration of all stakeholders that utilize and interact with the system, in its construction and implementation. This includes patients, families, medical providers, administrators, representatives from supporting industries, and policymakers.

Accelerating Patient Care

The Starzl Network is a Learning Health System designed to transform transplantation by combining transparency, best practices, and patient reported outcomes with innovative technology.

Key components include engaging patients and families as partners in the design of network priorities, database design, and tools to disseminate learning, implement knowledge, and improve practice.

Gaps Our Learning Health System Addresses


  • Pediatric transplantation is a rare disease
  • Variation in practice based on: Geographically, Age, and/or Center
  • Time to implementation and dissemination of knowledge is too long
  • Lack of evidence-based practice


  • Collaboration
  • Learning from other disciplines
  • Include patient voice
  • Integration of industry and tech partners •
  • Use improvement and research strategies

Support Opportunities

For a full list of Starzl Network support opportunities please click here

Please contact, C.J. Confair,, with any questions.